DK2168594T3 - Behandling af neoplasmer med neurotoxin - Google Patents
Behandling af neoplasmer med neurotoxin Download PDFInfo
- Publication number
- DK2168594T3 DK2168594T3 DK10000417.5T DK10000417T DK2168594T3 DK 2168594 T3 DK2168594 T3 DK 2168594T3 DK 10000417 T DK10000417 T DK 10000417T DK 2168594 T3 DK2168594 T3 DK 2168594T3
- Authority
- DK
- Denmark
- Prior art keywords
- cancer
- cells
- cell
- botulinum toxin
- botulinum
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Virology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Transplantation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Claims (6)
1. Anvendelse af en terapeutisk effektiv mængde af et farmaceutisk acceptabelt botulinum neurotoxin ved fremstilling af et medikament til behandling af en ikke-cancerøs sygdom hos et menneske, hvor sygdommen er en virus-medieret vækst, og hvor medikamentet er til injektion i et område, der omgiver det af denne sygdom angrebne væv således at en del af botulinum neurotoxinet omgiver, men ikke gennemtrænger det angrebne væv, og således at botulinum neurotoxinet svækker eller paralyserer musklen i det injicerede område.
2. Anvendelse ifølge krav 1, hvor medikamentet endvidere er til injektion i én eller flere lymfeknuder, der er beliggende lokalt eller distalt i forhold til det angrebne væv.
3. Anvendelse ifølge krav 1, hvor botulinumtoxinet er botulinum neurotoxin type A.
4. Anvendelse ifølge krav 1, hvor botulinumtoxinet er botulinum neurotoxin type B.
5. Anvendelse ifølge krav 1, hvor den virus-medierede vækst er en vorte.
6. Anvendelse ifølge krav 5, hvor vorten er verruca vulgaris.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61244304P | 2004-09-23 | 2004-09-23 | |
| EP05814023A EP1802339B1 (en) | 2004-09-23 | 2005-09-23 | Treating neoplasms with neurotoxin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2168594T3 true DK2168594T3 (da) | 2015-08-03 |
Family
ID=36090674
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05814023.7T DK1802339T3 (da) | 2004-09-23 | 2005-09-23 | Behandling af neoplasmer med neurotoxin |
| DK10000417.5T DK2168594T3 (da) | 2004-09-23 | 2005-09-23 | Behandling af neoplasmer med neurotoxin |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05814023.7T DK1802339T3 (da) | 2004-09-23 | 2005-09-23 | Behandling af neoplasmer med neurotoxin |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7709440B2 (da) |
| EP (4) | EP1802339B1 (da) |
| AT (1) | ATE525085T1 (da) |
| CA (2) | CA2875562A1 (da) |
| DK (2) | DK1802339T3 (da) |
| ES (3) | ES2548152T3 (da) |
| PT (2) | PT2168594E (da) |
| WO (1) | WO2006034404A2 (da) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2001270219A1 (en) * | 2000-06-28 | 2002-01-08 | Ira Sanders | Methods for using tetanus toxin for benificial purposes in animals (mammals) |
| US20090232849A1 (en) * | 2005-03-03 | 2009-09-17 | Universite Catholique De Louvain | Methods and compositions for the treatment of cancer |
| US8105611B2 (en) * | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
| ES2599033T3 (es) * | 2008-11-26 | 2017-01-31 | Toxcure, Inc. | Tratamiento de neoplasias con neurotoxina |
| US9744235B2 (en) | 2010-10-19 | 2017-08-29 | The Board Of Regents Of The University Of Oklahoma | Treatment of cardiovascular disorders with targeted nanoparticles |
| US10398668B2 (en) | 2010-10-19 | 2019-09-03 | The Board Of Regents Of The University Of Oklahoma | Glutamate treatment of cardiovascular disorders |
| US8740872B2 (en) | 2010-10-19 | 2014-06-03 | The Board Of Regents Of The University Of Oklahoma | Magnetically-targeted treatment for cardiac disorders |
| EP2649985A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis (III) |
| EP2649983A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis (II) |
| EP2649984A1 (en) | 2012-04-13 | 2013-10-16 | Lipotec, S.A. | Compounds which inhibit neuronal exocytosis |
| AU2013246882B2 (en) | 2012-04-13 | 2017-10-19 | Lubrizol Advanced Materials, Inc. | Compounds which inhibit neuronal exocytosis (II) |
| US9473152B2 (en) * | 2013-11-08 | 2016-10-18 | Taiwan Semiconductor Manufacturing Company, Ltd. | Coupling structure for inductive device |
| WO2016090196A1 (en) * | 2014-12-04 | 2016-06-09 | Autonomix Medical, Inc. | Systems and methods for regulating organ and/or tumor growth rates, function, and/or development |
| WO2018039090A1 (en) * | 2016-08-20 | 2018-03-01 | Gregg John Maicolm Hall | Methods of use & compositions of ibd, ibs, & antineoplastic microbial therapeutics |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU683275B2 (en) * | 1993-06-10 | 1997-11-06 | Allergan, Inc. | Multiple botulinum toxins for treating neuromuscular disorders and conditions |
| US5766605A (en) * | 1994-04-15 | 1998-06-16 | Mount Sinai School Of Medicine Of The City University Of New York | Treatment of autonomic nerve dysfunction with botulinum toxin |
| US7838007B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating mammary gland disorders |
| US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
| US6139845A (en) * | 1999-12-07 | 2000-10-31 | Allergan Sales, Inc. | Method for treating cancer with a neurotoxin |
| US6641820B1 (en) | 2000-01-19 | 2003-11-04 | Allergan, Inc. | Clostridial toxin derivatives and methods to treat pain |
| US6464986B1 (en) | 2000-04-14 | 2002-10-15 | Allegan Sales, Inc. | Method for treating pain by peripheral administration of a neurotoxin |
| US6565870B1 (en) | 2000-04-28 | 2003-05-20 | Allergan, Inc. | Methods for treating bone tumors |
| AU2001276005A1 (en) | 2000-08-02 | 2002-02-13 | Allergan Sales, Inc. | Method for treating a neoplasm |
| US20060134140A1 (en) | 2001-04-12 | 2006-06-22 | Dana Lasko | Compositions and methods for treating tumor spreading |
| DE10228103A1 (de) | 2002-06-24 | 2004-01-15 | Bayer Cropscience Ag | Fungizide Wirkstoffkombinationen |
| WO2004076634A2 (en) | 2003-02-24 | 2004-09-10 | Ira Sanders | Cell membrane translocation of regulated snare inhibitors , compositions therefor, and methods for treatment of disease |
| US8071550B2 (en) | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
| US7563748B2 (en) | 2003-06-23 | 2009-07-21 | Cognis Ip Management Gmbh | Alcohol alkoxylate carriers for pesticide active ingredients |
| US8048423B2 (en) * | 2003-12-09 | 2011-11-01 | Allergan, Inc. | Botulinum toxin therapy for skin disorders |
| RU2346996C2 (ru) | 2004-06-29 | 2009-02-20 | ЮРОПИЭН НИКЕЛЬ ПиЭлСи | Усовершенствованное выщелачивание основных металлов |
| US8343929B2 (en) * | 2004-09-23 | 2013-01-01 | Toxcure, Inc. | Treating neoplasms with neurotoxin |
| US20090232849A1 (en) | 2005-03-03 | 2009-09-17 | Universite Catholique De Louvain | Methods and compositions for the treatment of cancer |
| US8105611B2 (en) * | 2005-06-17 | 2012-01-31 | Allergan, Inc. | Treatment of autoimmune disorder with a neurotoxin |
-
2005
- 2005-09-23 WO PCT/US2005/033982 patent/WO2006034404A2/en active Application Filing
- 2005-09-23 EP EP05814023A patent/EP1802339B1/en not_active Not-in-force
- 2005-09-23 EP EP20100000417 patent/EP2168594B1/en not_active Not-in-force
- 2005-09-23 EP EP10012869.3A patent/EP2298339B1/en not_active Not-in-force
- 2005-09-23 DK DK05814023.7T patent/DK1802339T3/da active
- 2005-09-23 US US11/577,838 patent/US7709440B2/en not_active Expired - Fee Related
- 2005-09-23 PT PT100004175T patent/PT2168594E/pt unknown
- 2005-09-23 ES ES10000417.5T patent/ES2548152T3/es active Active
- 2005-09-23 DK DK10000417.5T patent/DK2168594T3/da active
- 2005-09-23 ES ES10012869.3T patent/ES2555856T3/es active Active
- 2005-09-23 CA CA2875562A patent/CA2875562A1/en not_active Abandoned
- 2005-09-23 EP EP15002090.7A patent/EP2985034A1/en not_active Withdrawn
- 2005-09-23 CA CA2586793A patent/CA2586793C/en not_active Expired - Fee Related
- 2005-09-23 PT PT05814023T patent/PT1802339E/pt unknown
- 2005-09-23 AT AT05814023T patent/ATE525085T1/de active
- 2005-09-23 ES ES05814023T patent/ES2373963T3/es active Active
-
2010
- 2010-03-17 US US12/725,955 patent/US8435951B2/en not_active Expired - Fee Related
-
2013
- 2013-05-02 US US13/875,542 patent/US20130236497A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1802339B1 (en) | 2011-09-21 |
| EP2985034A1 (en) | 2016-02-17 |
| PT1802339E (pt) | 2011-12-15 |
| CA2586793C (en) | 2015-03-24 |
| PT2168594E (pt) | 2015-09-15 |
| EP2168594B1 (en) | 2015-04-29 |
| EP2168594A1 (en) | 2010-03-31 |
| ES2548152T3 (es) | 2015-10-14 |
| CA2875562A1 (en) | 2006-03-30 |
| US20130236497A1 (en) | 2013-09-12 |
| CA2586793A1 (en) | 2006-03-30 |
| EP2298339A1 (en) | 2011-03-23 |
| EP1802339A2 (en) | 2007-07-04 |
| ES2373963T3 (es) | 2012-02-10 |
| US7709440B2 (en) | 2010-05-04 |
| ATE525085T1 (de) | 2011-10-15 |
| WO2006034404A3 (en) | 2006-08-10 |
| ES2555856T3 (es) | 2016-01-11 |
| EP2298339B1 (en) | 2015-07-15 |
| DK1802339T3 (da) | 2011-10-24 |
| WO2006034404A2 (en) | 2006-03-30 |
| EP1802339A4 (en) | 2008-03-05 |
| US8435951B2 (en) | 2013-05-07 |
| US20100209456A1 (en) | 2010-08-19 |
| US20090028972A1 (en) | 2009-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2168594T3 (da) | Behandling af neoplasmer med neurotoxin | |
| JP4037652B2 (ja) | 神経毒を含む痛み処置製剤 | |
| JP4851039B2 (ja) | 疼痛処置方法 | |
| TWI284536B (en) | Novel use of botulinum in the treatment of parathyroid and calcemia disorders | |
| JP5594962B2 (ja) | 神経毒による自己免疫疾患の治療 | |
| JP2012116839A (ja) | 膵臓障害の処置方法 | |
| US20130177548A1 (en) | Treating neoplasms with neurotoxin | |
| AU2009319732B2 (en) | Treating neoplasms with neurotoxin | |
| AU2016202748A1 (en) | Treating neoplasms with neurotoxin | |
| AU2013213713A1 (en) | Treating neoplasms with neurotoxin | |
| US20160375112A1 (en) | Reducing Adverse Side Effects of a Compound by a Neurotoxin |